Summit Therapeutics (SMMT) Change in Cash (2017 - 2026)

Summit Therapeutics (SMMT) has 10 years of Change in Cash data on file, last reported at $312.9 million in Q2 2026.

• Quarterly Change in Cash rose 262.32% year-over-year to $312.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $121.5 million (down 54.91% YoY) and the FY2025 annual result came in at $120.4 million, up 256.6% from the prior year.
• Change in Cash improved to $312.9 million in Q2 2026, from -$118.8 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $526.6 million in Q4 2022 to a low of -$577.6 million in Q1 2023.
• A 5-year average of $19.3 million and a median of -$2.1 million in 2022 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2022 — Change in Cash jumped 6327.22% — and 2023, when it slumped 10307.42%.
• Tracing SMMT's Change in Cash over 5 years: stood at $526.6 million in 2022, then slumped by 90.96% to $47.6 million in 2023, then sank by 76.72% to $11.1 million in 2024, then tumbled by 219.88% to -$13.3 million in 2025, then surged by 2453.5% to $312.9 million in 2026.
• The last three Change in Cash figures came in at $312.9 million (Q2 2026), -$118.8 million (Q1 2026), and -$13.3 million (Q4 2025), per Business Quant data.